Immuno-Oncology: Emerging Targets and Combination Therapies

Immuno-Oncology: Emerging Targets and Combination Therapies

Host immunity recognizes and eliminates most early tumor cells, yet immunological checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to effective antitumor immune responses. T-lymphocyte co-inhibitory pathways influence intensity, inflammation and duration of antitumor...

Full description

Bibliographic Details
Main Authors: Henry T. Marshall, Mustafa B. A. Djamgoz
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Oncology
Subjects:
combination immunotherapy
tumor microenvironment
checkpoint blockade
personalized therapy
biomarkers
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00315/full

Similar Items

Similar Items